Usoro ọgwụgwọ cellular ọ bụ ọdịnihu nke ọrịa autoimmune?
Ngwọta mgbanwe maka ọrịa cancer nwekwara ike ịgwọ ma tọgharịa usoro ahụ ji alụso ọrịa ọgụ iji nye mgbaghara ogologo oge ma ọ bụ ikekwe ọbụna gwọọ ụfọdụ ọrịa autoimmune.
Chimeric antigen receptor (CAR) T-cell ọgwụgwọ enyela usoro ọhụụ maka ịgwọ ọrịa kansa hematologic kemgbe 2017, mana enwere akara mmalite na enwere ike nwetaghachi immunotherapies cellular ndị a maka ọrịa autoimmune mgbasa ozi B-cell.
N'ọnwa Septemba nke afọ gara aga, ndị nchọpụta na Germany kọrọ na ndị ọrịa ise nwere lupus erythematosus refractory systemic lupus erythematosus (SLE) ejiri ọgwụgwọ CAR T-cell gwọọ ha niile nwetara mgbaghara n'enweghị ọgwụ. N'oge e bipụtara ya, ọ nweghị onye ọrịa laghachiri azụ ruo ọnwa 17 ka a gwọchara ya. Ndị na-ede akwụkwọ kọwara seroconversion nke ọgwụ nje antinuclear n'ime ndị ọrịa abụọ na-esochi ogologo oge, "na-egosi na mkpochapụ nke autoimmune B-cell clones nwere ike iduga na mgbaziwanye nke autoimmunity," ndị nchọpụta dere.
N'okwu ikpe ọzọ e bipụtara na June, ndị nchọpụta jiri CD-19 ezubere iche maka mkpụrụ ndụ CAR-T iji gwọọ nwoke dị afọ 41 nwere ọrịa antisynthetase refractory na myositis na-aga n'ihu na ọrịa ngụgụ interstitial. Ọnwa isii mgbe ọgwụgwọ gasịrị, ọ dịghị ihe ịrịba ama nke myositis na MRI na nyocha CT na-egosi nhụsianya zuru oke nke alveolitis.
Kemgbe ahụ, ụlọ ọrụ biotechnology abụọ - Cabaletta Bio na Philadelphia na Kyverna Therapeutics na Emeryville, California - enyelarị aha ngwa ngwa sitere na nchịkwa nri na ọgwụ ọjọọ nke US maka ọgwụgwọ CAR T-cell maka SLE na lupus nephritis. Bristol-Myers Squibb na-emekwa nnwale nke nkeji 1 na ndị ọrịa nwere SLE siri ike. Ọtụtụ ụlọ ọrụ biotechnology na ụlọ ọgwụ dị na China na-eme nnwale ụlọ ọgwụ maka SLE. Ma nke a bụ naanị ọnụ ọnụ iceberg banyere ọgwụgwọ cellular maka ọrịa autoimmune, Max Konig, MD, PhD, onye osote prọfesọ nke ọgwụ na ngalaba nke rheumatology na Johns Hopkins University School of Medicine na Baltimore kwuru.
"Ọ bụ oge na-akpali akpali nke ukwuu. Ọ bụ ihe a na-enwetụbeghị ụdị ya na akụkọ ihe mere eme nke autoimmunity," ka o kwuru.
A "Reboot" maka Immune System
Usoro ọgwụgwọ ezubere iche nke B-cell adịla kemgbe mmalite afọ 2000 na ọgwụ dị ka rituximab, ọgwụ mgbochi monoclonal nke na-elekwasị anya CD20, antigen gosipụtara n'elu sel B. Mkpụrụ ndụ CAR T dị ugbu a na-elekwasị anya antigen ọzọ dị elu, CD19, ma bụrụ ọgwụgwọ kachasị ike karị. Ha abụọ na-arụ ọrụ nke ọma n'ibelata mkpụrụ ndụ B n'ime ọbara, mana sel T ndị a ezubere iche CD19 nwere ike iru mkpụrụ ndụ B nọ ọdụ n'anụ ahụ n'ụzọ ọgwụgwọ mgbochi mmadụ enweghị ike, Konig kọwara.